

TOP 50 CHEMOTHERAPY AND TARGETED CANCER PRODUCTS, 2012

Category leaders, ranked by 2012 US sales, and their journal spend

Rank	Product	Manufacturer	US sales dollars (millions)	% change vs. prior 12 mos.	2012 US journal spend dollars (thousands)	% change vs. prior 12 mos.	2011 US journal spend dollars (thousands)	% change vs. prior 12 mos.
1	Rituxan	Genentech/Roche	\$3,197.2	8.0%	\$0.0	N/A	\$0.0	-100.0%
2	Avastin	Genentech/Roche	\$2,660.9	0.0%	\$1,523.0	-37.9%	\$2,451.0	-29.1%
3	Herceptin	Genentech/Roche	\$1,854.3	12	\$0.0	-100.0%	\$1,344.0	-20.0%
4	Gleevec	Novartis	\$1,816.7	13.0%	\$0.0	-100.0%	\$498.0	-36.6%
5	Alimta	Eli Lilly	\$1,160.2	11.0%	\$92.0	-92.3%	\$1,182.0	-20.2%
6	Eloxatin	Sanofi	\$1,149.9	-5.0%	\$0.0	N/A	\$0.0	N/A
7	Xeloda	Genentech/Roche	\$724.3	8.0%	\$22.0	-96.0%	\$538.0	-23.0%
8	Velcade	Takeda	\$714.6	4.0%	\$1,564.0	>100.0%	\$589.0	39.4%
9	Erbix	BMS/Imclone	\$690.4	-2.0%	\$749.0	-70.3%	\$2,522.0	37.2%
10	Xgeva	Amgen	\$663.4	85.0%	\$2,346.0	-2.4%	\$2,404.0	>100.0%
11	Tarceva	Genentech/Roche	\$626.2	6.0%	\$419.0	-66.1%	\$1,236.0	-16.2%
12	Treanda	Cephalon/Teva	\$605.9	21.0%	\$1,365.0	-1.8%	\$1,389.0	15.7%
13	Revlimid	Celgene	\$555.9	25.0%	\$0.0	N/A	\$0.0	-100.0%
14	Yervoy	Bristol-Myers Squibb	\$532.7	52.0%	\$823.0	-39.7%	\$1,365.0	N/A
15	Zytiga	Johnson & Johnson	\$498.6	>100.0%	\$5,211.0	>100.0%	\$1,339.0	N/A
16	Docetaxel	Generic	\$472.7	-14.0%	\$0.0	-100.0%	\$72.0	N/A
17	Afinitor	Novartis	\$422.8	>100.0%	\$1,307.0	9.2%	\$1,197.0	-60.7%
18	Temodar	Merck	\$419.3	3.0%	\$112.0	-83.2%	\$667.0	>100.0%
19	Sprycel	Bristol-Myers Squibb	\$411.0	37.0%	\$568.0	-51.4%	\$1,168.0	81.1%
20	Tasigna	Novartis	\$400.0	40.0%	\$1,218.0	-22.5%	\$1,571.0	-28.1%
21	Vidaza	Celgene	\$362.0	11.0%	\$0.0	N/A	\$0.0	N/A
22	Abraxane	Celgene	\$361.0	4.0%	\$618.0	21.2%	\$510.0	N/A
23	Sutent	Pfizer	\$337.0	8.0%	\$299.0	-65.6%	\$869.0	-69.4%
24	Faslodex	AstraZeneca	\$310.1	14.0%	\$0.0	N/A	\$0.0	N/A
25	Dacogen	Eisai	\$253.9	10.0%	\$79.0	-81.0%	\$416.0	-8.6%
26	Cyclophosphamide	Generic	\$235.7	82.0%	\$0.0	N/A	\$0.0	N/A
27	Lupron Depot-3 mo.	AbbVie	\$210.8	-3.0%	\$0.0	N/A	\$0.0	N/A
28	Votrient	GlaxoSmithKline	\$174.1	57.0%	\$1,552.0	54.7%	\$1,003.0	>100.0%
29	Halaven	Eisai	\$148.7	23.0%	\$711.0	-32.3%	\$1,051.0	>100.0%
30	Jevtana	Sanofi	\$146.8	-24.0%	\$12.0	-92.9%	\$176.0	>100.0%
31	Zelboraf	Genentech/Roche	\$130.2	>100.0%	\$1,380.0	58.1%	\$873.0	N/A
32	Vectibix	Amgen	\$129.9	0.0%	\$0.0	-100.0%	\$641.0	-24.5%
33	Tykerb	GlaxoSmithKline	\$127.7	7.0%	\$468.0	N/A	\$0.0	-100.0%
34	Lupron Depot-4 mo.	AbbVie	\$106.9	-27.0%	\$0.0	N/A	N/A	N/A
35	Fluorouracil	Generic	\$100.0	10.0%	\$0.0	N/A	\$0.0	N/A
36	Lupron Depot	AbbVie	\$98.8	-4.0%	\$0.0	N/A	\$0.0	N/A
37	Gemcitabine HCl	Generic	\$85.9	-77.0%	\$0.0	-100.0%	\$124.0	N/A
38	Megace ES	Par Pharmaceuticals	\$85.5	-7.0%	\$0.0	N/A	\$0.0	N/A
39	Clolar	Genzyme/Sanofi	\$83.0	9.0%	\$0.0	N/A	\$0.0	N/A
40	Lupron Depot-6 mo.	AbbVie	\$83.0	>100.0%	\$0.0	N/A	\$0.0	N/A
41	Oxaliplatin	Generic	\$81.1	-74.0%	\$25.0	N/A	\$0.0	N/A
42	LipoDox	Sun Pharma	\$77.9	N/A	\$0.0	N/A	\$0.0	N/A
43	Melphalan HCl	Generic	\$76.2	5.0%	\$0.0	N/A	\$0.0	N/A
44	Exemestane	Generic	\$76.0	49.0%	\$0.0	N/A	\$0.0	N/A
45	Eligard	Sanofi	\$75.4	-8.0%	\$0.0	N/A	\$0.0	N/A
46	Ixempra	Bristol-Myers Squibb	\$71.6	-14.0%	\$413.0	7.8%	\$383.0	-23.2%
47	Torisel	Pfizer	\$70.4	-3.0%	\$58.0	-93.5%	\$894.0	-32.9%
48	Arzerra	GlaxoSmithKline	\$69.2	19.0%	\$1,008.0	30.0%	\$775.0	7.9%
49	Methotrexate Sod	Generic	\$68.2	21.0%	\$0.0	N/A	\$0.0	N/A
50	Xalkori	Pfizer	\$67.7	>100.0%	\$1,059.0	31.8%	\$803.0	N/A